Omnicell (NASDAQ:OMCL) Shares Gap Down – Here’s What Happened

Shares of Omnicell, Inc. (NASDAQ:OMCL) gapped down before the market opened on Thursday . The stock had previously closed at $41.40, but opened at $35.54. Omnicell shares last traded at $36.8760, with a volume of 528,962 shares changing hands.

Omnicell News Roundup

Here are the key news stories impacting Omnicell this week:

• Positive Sentiment: Omnicell reported second-quarter adjusted EPS of $0.94, well above the $0.47–$0.48 consensus, while revenue rose 7.4% year over year to $312.2 million and also exceeded estimates. GAAP net income increased to $24 million from $6 million a year earlier. Omnicell Q2 Earnings and Revenues Top Estimates
• Positive Sentiment: Management raised its full-year 2026 non-GAAP EPS outlook to $2.15–$2.30, above the roughly $1.81 analyst consensus, and lifted its full-year revenue outlook to $1.225–$1.245 billion. Demand for connected devices, technical services and SaaS offerings, along with cost controls and tariff refunds, supported results. Omnicell Q2 Non-GAAP Net Income, Revenue Increase; 2026 Non-GAAP EPS Outlook Lifted
• Positive Sentiment: Omnicell highlighted momentum in its Titan XT and OmniSphere platforms, pointing to pipeline growth and longer-term opportunities in medication-management automation. KeyCorp maintained an “overweight” rating, although it reduced its price target from $70 to $65. OMCL Q2 Earnings Call Highlights Titan XT Pipeline Growth

Analysts Set New Price Targets

OMCL has been the subject of a number of recent analyst reports. Weiss Ratings raised shares of Omnicell from a “sell (d)” rating to a “hold (c-)” rating in a report on Thursday, May 7th. Wall Street Zen raised shares of Omnicell from a “buy” rating to a “strong-buy” rating in a research note on Sunday, May 10th. Wells Fargo & Company dropped their target price on Omnicell from $55.00 to $50.00 and set an “overweight” rating on the stock in a research report on Friday. KeyCorp cut their price target on Omnicell from $70.00 to $65.00 and set an “overweight” rating for the company in a research note on Friday. Finally, Zacks Research cut Omnicell from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 7th. Seven research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat.com, Omnicell presently has a consensus rating of “Moderate Buy” and a consensus price target of $58.43.

Omnicell Trading Down 4.7%

The company has a fifty day moving average of $41.97 and a 200-day moving average of $41.09. The company has a current ratio of 1.64, a quick ratio of 1.29 and a debt-to-equity ratio of 0.13. The company has a market capitalization of $1.61 billion, a price-to-earnings ratio of 42.11, a PEG ratio of 0.96 and a beta of 0.96.

Omnicell (NASDAQ:OMCL) last announced its earnings results on Thursday, July 30th. The company reported $0.94 EPS for the quarter, beating analysts’ consensus estimates of $0.47 by $0.47. The business had revenue of $312.21 million during the quarter, compared to analysts’ expectations of $310.21 million. Omnicell had a return on equity of 5.66% and a net margin of 3.13%.The business’s revenue was up 7.4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.45 earnings per share. Omnicell has set its Q3 2026 guidance at 0.350-0.430 EPS and its FY 2026 guidance at 2.150-2.300 EPS. As a group, equities research analysts anticipate that Omnicell, Inc. will post 1.31 earnings per share for the current fiscal year.

Insider Activity at Omnicell

In related news, EVP Corey J. Manley sold 5,025 shares of the business’s stock in a transaction that occurred on Monday, May 18th. The stock was sold at an average price of $43.22, for a total transaction of $217,180.50. Following the completion of the sale, the executive vice president directly owned 112,783 shares in the company, valued at approximately $4,874,481.26. The trade was a 4.27% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Nnamdi Njoku sold 3,090 shares of the stock in a transaction on Monday, May 18th. The shares were sold at an average price of $43.22, for a total value of $133,549.80. Following the completion of the transaction, the executive vice president directly owned 154,785 shares of the company’s stock, valued at approximately $6,689,807.70. This represents a 1.96% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 2.92% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Omnicell

A number of hedge funds have recently modified their holdings of OMCL. Dimensional Fund Advisors LP raised its position in shares of Omnicell by 6.0% in the first quarter. Dimensional Fund Advisors LP now owns 2,450,385 shares of the company’s stock valued at $81,791,000 after buying an additional 137,834 shares during the last quarter. Wellington Management Group LLP boosted its position in Omnicell by 156.4% during the fourth quarter. Wellington Management Group LLP now owns 2,075,362 shares of the company’s stock worth $94,014,000 after acquiring an additional 1,265,818 shares during the last quarter. Lazard Asset Management LLC grew its stake in Omnicell by 3.8% during the 2nd quarter. Lazard Asset Management LLC now owns 1,708,345 shares of the company’s stock valued at $50,225,000 after acquiring an additional 62,733 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. grew its stake in Omnicell by 2.0% during the 1st quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,410,865 shares of the company’s stock valued at $47,095,000 after acquiring an additional 27,497 shares in the last quarter. Finally, Geode Capital Management LLC raised its holdings in Omnicell by 1.0% in the 4th quarter. Geode Capital Management LLC now owns 1,127,583 shares of the company’s stock valued at $51,088,000 after acquiring an additional 11,424 shares during the last quarter. 97.70% of the stock is currently owned by institutional investors and hedge funds.

About Omnicell

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.